Exploring the role of therapeutic drug monitoring and regular supervision in optimizing quality of life in patients of bipolar affective disorder receiving lithium therapy in a tertiary care teaching hospital: a prospective observational study
DOI:
https://doi.org/10.18203/2320-6012.ijrms20203090Keywords:
Bipolar affective disorder, Health related quality of life, Lithium, Medication Adherence Rating Scale, Medication adherence, Montgomery-Asberg Depression Scale, Therapeutic drug monitoring, WHO Quality Of Life ScoreAbstract
Background: Lithium is considered first line drug effective in treating manic and mixed episodes of bipolar affective disorders throughout the globe. But the chronic and heterogenous nature of disease, along with toxicity of lithium often make patients non-adherent to medication as well as diminished health related quality of life. Present study was done to find out the prospect of regular supervision and follow up with therapeutic drug monitoring in optimization of lithium therapy based on health-related quality of life outcomes.
Methods: It was a prospective, non-randomized, observational study of a cohort of subjects who are suffering from bipolar affective disorders and on lithium therapy. Patients were regularly followed up with therapeutic drug monitoring and personalized interview with questionnaires like WHO Quality of Life Score (QOL-Bref), Montgomery-Asberg Depression Scale (MADRS) and Medication Adherence Rating Scale (MARS).
Results: Results revealed there was significant improvement in health-related quality of life of patients who were monitored with therapeutic drug monitoring and prescribed lithium therapy.
Conclusions: Hence to maintain patients’ quality of life improved throughout the cycle of bipolar disorder spectrum, regular follow-up visits with monitoring of serum levels of lithium is needed, so that adverse effects would be minimal and adherence to medication become optimal. These optimal dosing resulting in optimal benefit to patients can be achieved with the involvement of clinical pharmacological consultation.
References
Volkmann C, Bschor T, Kohler S. Lithium Treatment Over the Lifespan in Bipolar Disorders. Front Psychiatr. 2020;11:377.
Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet. 2016;387(10027):1561-72.
Organization WH. The World Health Report 2002: Reducing Risks, Promoting Healthy Life. Geneva: World Health Organization; 2002.
McCreadie RG, McCormick, M, Morrison, DP. The impact of lithium in South-West Scotland. III. The discontinuation of lithium. Br J Psychiatr. 1985;146:77-80.
Mitchell PB. Therapeutic drug monitoring of psychotropic medications. Br J Clin Pharmacol. 2000;49(4):303-12.
Touw DJ, Neef C, Thomson AH, Vinks AA. Cost-effectiveness of therapeutic drug monitoring: a systemic review. Ther Drug Monit. 2005;27:10-7.
Goodwin FK, Jamison KR. Manic-depressive illness. Oxford University Press;1990.
Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011;35(3):804-17.
Petkari E, Pietschnig J. Associations of Quality of Life with Service Satisfaction in Psychotic Patients: A Meta-Analysis. PLoS One. 2015;10(8):e0135267.
The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med. 1995;41(10):1403-9.
WHOQOL-BREF Questionnaire. Available at: https://www.who.int/healthinfo/survey/whoqol-qualityoflife/en/index5.html. Accessed 13 June 2019.
Montgomery and Asberg Depression Rating Scale (MADRS). Available at: http://www.veale.co.uk/wp content/uploads/2010/10/MADRS.pdf.
Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000;42(3):241-7.
American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159(suppl 4):1-50.
Bellack AS, Bowden CL, Bowie CR, Byerly MJ, Carpenter WT, Copeland LA, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. Journal of clinical psychiatry. 2009;70(SUPPL. 4):1-48.
Altman S, Haeri S, Cohen LJ, Ten A, Barron E, Galynker II, Duhamel KN. Predictors of relapse in bipolar disorder: a review. J Psychiatr Pract.2006;12(5):269-82.
Keck Jr PE, McElroy SL, Strakowski SM, Stanton SP, Kizer DL, Balistreri TM, et al. Factors associated with pharmacologic noncompliance in patients with mania. J Clin Psychiatry. 1996;57(7):292-7.
Vieta E. Improving treatment adherence in bipolar disorder through psychoeducation. J Clin Psychiatry. 2005;66(suppl 1):24-9.
Benkert O, Hippius H. Kompendium der psychiatrischen Pharmakotherapie. 2nd edition. Springer Verlag, Berlin Heidelberg, Germany; 2000.
National Patient Safety Agency (NPSA). Patient Safety Alert NPSA 2009/PSA005 Safer lithium therapy. Available at: https://www.sps.nhs.uk/wp-content/uploads/2018/02/2009-NRLS-0921-Safer-lithium-tmation-2010.01.12-v1.pdf.
Nederlof M, Heerdink ER, Egberts AC, Wilting I, Stoker LJ, Hoekstra R et al. Monitoring of patients treated with lithium for bipolar disorder: an international survey. Int J Bipolar Disord. 2018;6(1):12.
Kupka RW, Goossens P, van Bendegem M, Daemen P, Daggenvoorde T, Daniels M, et al. Dutch multidisciplinary guideline bipolar disorder. Nederlandse Vereniging voor Psychiatrie (NVvP); 2015.
Harrison PJ, Cipriani A, Harmer CJ, Nobre AC, Saunders K, Goodwin GM, et al. Innovative approaches to bipolar disorder and its treatment. Ann N Y Acad Sci. 2016;1366(1):76-89.
